Where to Find the Cheapest Faslodex Price

Our most recent US pharmacy data shows a low of roughly $291.75 for Fulvestrant with a standard discount card. That figure moves with dosage and quantity — check the comparison table for the exact combination you need.

Generic and brand-name pricing for Fulvestrant is broken out in the tables above where both exist in our data. Generic versions are typically the lower-cost option, but availability depends on the specific formulation and dosage.

Since Faslodex is administered in a clinical setting, patients do not purchase it directly from a pharmacy. Hospitals or clinics procure it from specialty distributors. Without insurance, the list price for the medication can be high, often in the range of several thousand dollars per treatment cycle. However, the final cost to an uninsured patient depends on the pricing policy of the administering facility and any patient assistance programs they utilize. Some clinics may accept savings cards or coupons that can substantially lower the patient's responsibility. It's essential to discuss payment options and potential financial aid directly with your treatment center's billing department or case manager.

Medicare typically covers Faslodex under Part B (Medical Insurance) because it is administered by a healthcare professional in a clinic or hospital outpatient setting. When covered by Part B, beneficiaries are usually responsible for 20% of the Medicare-approved amount after meeting the Part B deductible. Many patients have supplemental Medigap or Medicare Advantage plans that may cover some or all of this coinsurance. It is not typically covered under Part D prescription drug plans. For beneficiaries concerned about costs, manufacturer patient assistance programs or other independent non-profit foundations may offer financial support. Your hospital's case manager or social worker can provide guidance on eligibility for these resources.

Yes. The active ingredient in brand-name Faslodex is fulvestrant. Generic fulvestrant injections, which are therapeutically equivalent, are manufactured by several companies, including Apotex, Glenmark, and Mylan. The availability of the generic can lead to lower costs for healthcare facilities, which may translate to savings for patients depending on their insurance or the clinic's pricing structure.